⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10392865 | 0.80 | P2RX3 (0.47) | — | |
| SCHEMBL27853613 | 0.78 | CHEK1 (0.53) | — | |
| SCHEMBL11534257 | 0.78 | TRPV4 (0.36) | — | |
| SCHEMBL2057028 | 0.76 | — | — | |
| SCHEMBL30393465 | 0.76 | — | — | |
| SCHEMBL11894260 | 0.76 | — | — | |
| SCHEMBL23882752 | 0.76 | S1PR3 (0.41) | — | |
| SCHEMBL12230430 | 0.76 | S1PR3 (0.39) | — | |
| SCHEMBL2011764 | 0.74 | PIK3CD (0.52) | — | |
| SCHEMBL12630708 | 0.73 | CHEK1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362149-A | SHP2 inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-12624006-B2 | Process for the preparation of 5-(1-cyanocyclopropyl)-pyridine-2-carboxylic acid esters amides and nitriles | SYNGENTA CROP PROTECTION AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2026-01-01 | — | — | US | disclosed |
| US-20250374828-A1 | ORGANIC COMPOUND | SEMICONDUCTOR ENERGY LAB (JP) | 2025-12-04 | — | — | US | disclosed |
| US-20250331420-A1 | Organic Compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-10-23 | — | — | US | disclosed |
| US-12448371-B2 | Inhibitor compounds | Cincera Therapeutics Pty Ltd (AU) | 2025-10-21 | — | — | US | disclosed |
| CN-119874468-A | Novel method for introducing alkyl on nitrogen-containing heterocyclic molecule by photocatalytic C-Cl bond activation | 扬州大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-4532486-A1 | PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-5750545-A | EXHIBIT EOSINOPHIL-INHIBITORY ACTION AND LYMPHOCYTE ACTIVATION-INHIBITORY ACTION; USEFUL FOR TREATMENT OF IMMUNE-RELATED DISEASES | THE GREEN CROSS CORPORATION (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0710654-A1 | TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-08 | — | — | EP | disclosed |